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A. Introduction and aims 
The goal of pharmaceutical research is the specific and effective manipulation of 
disease-modifying targets, which is ideally achieved by small molecules binding to the 
macromolecule with high affinity. However, it is still a challenging task to inhibit 
molecular interactions where large surface areas or solvent-exposed binding sites are 
involved. Macromolecules which could not be efficiently modulated by drug-like 
small molecules are designated as undruggable proteins. For the inhibition of these 
targets, a potential solution might be to exploit designed non-natural folded polymers 
(foldamers), which have emerged as promising materials for biomolecule recognition. 
We have investigated two medicinally relevant targets: the immunosuppressant, 
angiogenic and tumour-nursing Galectin-1 (Gal-1) homodimer, whose inhibition might 
result in antimetastatic and antiangiogenic drugs; and the synaptotoxic Amyloid β1-42 
(Aβ1-42) fibrils and oligomers, which are among the major causative agents of 
Alzheimer’s disease. The inhibition of Gal-1 and Aβ1-42 aggregates is difficult due to 
their solvent-exposed binding site and the absence of distinct binding pockets. 
For studies of the protein–ligand systems, we have used primarily nuclear 
magnetic resonance (NMR) spectroscopy, which has become a powerful and versatile 
technique for the characterization of biomolecules and for the detection of molecular 
interactions. NMR can be exploited in the process of preclinical drug discovery by 
finding initial hits through screening, supporting lead optimization, fragment-based 
drug design and obtaining structure-activity relationships (SAR). As opposed to its 
complementary method X-ray crystallography, NMR can be used to investigate 
protein–ligand systems in a biologically more relevant medium, solution. Thus, 
molecular motions, which are confined to the solution phase, can also be captured. The 
atomic-level structural and dynamic information gained on biomolecules and their 
complexes from NMR studies can facilitate an understanding of their functions and 
mechanisms of action and can be utilized in structure-based drug design for the 
rational improvement of ligands. 
Our primary aim was to gain information about our targets by means of NMR 
spectroscopic techniques, which can promote the structure-based design of new Gal-1-
binding compounds and Aβ1-42 inhibitors. We aimed to optimize, validate and 
improve binding tests which can be efficiently used in an NMR screening process for 
new inhibitors. In the case of Gal-1, the NMR signal assignment of the labelled protein 
was a prerequisite for the experiments, so we set out to assign the backbone 
resonances of 15N/13C-labelled Gal-1. As a first step, the investigation of the proteins 
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alone and/or in the presence of their natural or literature peptide ligands was targeted. 
The goal was to characterize their interactions and to obtain relevant information about 
the mode of action of the ligands. Finally, we planned to utilize the techniques and 
structural/dynamic information in drug discovery, most favourably, for the design of 
foldamer type ligands of the proteins. In order to support and explain the NMR results 
and test new compounds, the measurements were supplemented with other biophysical 
techniques and with biological experiments, such as isothermal titration calorimetry 
(ITC), particle size measurements and enzyme-linked immunosorbent assay (ELISA). 
B. Methods 
Ligand-detected NMR experiments 
The interactions of Gal-1, asialofetuin (ASF) and Aβ1-42 and their ligands were 
characterized via ligand-observed NMR methods, which included saturation transfer 
difference (STD), transferred nuclear Overhauser effect (trNOE) and signal quenching 
experiments. For conventional 1H STD experiments, the selective saturation of the 
protein was achieved via Gaussian-shaped pulses. For the trNOE experiments, 2D 
NOESY measurements were performed with and without the protein. The techniques 
were used for the following samples: 
(i) Gal-1 or ASF and literature with Tyr-Xxx-Tyr type peptide ligands (TYDYF-NH2, 
WYKYW-NH2, TYDYFR-NH2 and TYPYFR-NH2) or lactose, 
(ii) fibrillar Aβ1-42 with neuroprotective pentapeptides (LPFFD, LPYFD-NH2, 
FRHDS-NH2 and RIIGL-NH2) and/or Thioflavin T (ThT), 
(iii) Aβ1-42 oligomers with foldamer peptides.  
With the aim of improving the methodology, different excitation schemes were 
probed for STD experiments. In the group-selective STD (GS-STD), the samples 
contained lactose complexed with 15N/13C-labelled Gal-1. For the selective saturation 
of the protein, a train of BIRDd pulses was applied. For the aliphatic/aromatic 13C 
GS-STD spectra, the band-selective inversion of carbon was obtained with a Q3 
Gaussian cascade of 256 ms within the BIRDd cycle. 
Protein-detected NMR experiments 
Protein-detected experiments were used for 15N/13C-Gal-1. For the resonance 
assignment of the protein, 3D HNCO, HNCA, HN(CO)CA, HN(CA)CO, 
CBCA(CO)NH, HBHA(CO)NH and 15N-NOESY-HSQC experiments were recorded 
and analyzed. In the 15N Heteronuclear Single Quantum Coherence (HSQC) titration 
experiments, 15N HSQC spectra of 15N-labelled Gal-1 were recorded for the protein 
alone and with increasing ligand (lactose or Tyr-Xxx-Tyr peptides) concentrations. In 
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order to explore the dynamic behaviour of Gal-1 in solution, T1, T2 relaxation and 
heteronuclear NOE experiments were recorded for samples of Gal-1 with and without 
lactose, and model-free analysis was carried out. 
Isothermal titration calorimetry for Aβ1-42 oligomers and foldamers 
Isothermal titrations were performed for Aβ1-42 oligomers and foldamers with a 
Microcal VP-ITC microcalorimeter. The experimental data were fitted to the two-
independent-site binding model.  
Other methods 
The binding of Tyr-Xxx-Tyr peptides to Gal-1 was investigated by ELISA test for 
the binding of Gal-1 to ASF in the presence of competitors and by flow cytometric 
analysis of Gal-1 binding to cells. Time-dependent signal intensity loss and 
quantitative NMR spectroscopic binding tests for the Aβ1-42 fibril samples were 
complemented with Dynamic Light Scattering (DLS), Transmission Electron 
Microscopy (TEM) and ζ-potential measurements. The interaction of the multivalent 
foldamer and Aβ1-42 oligomers was characterized by several biophysical methods. 
C. Results and discussion 
1. The solution-phase behaviour of the tumour-nursing protein Gal-1 was characterized 
by means of NMR spectroscopy in the absence and in the presence of its natural 
ligand lactose. 
1.1. The backbone chemical shifts of 15N/13C-labelled Gal-1 could be successfully 
assigned at physiological pH 7.4 and the great majority of the CB and HB 
resonances were also identified. 
1.2.  15N HSQC titrations showed that lactose binding affects the structure of Gal-1 
even remote from the CRD, on the opposite side of the protein (Figure 1). 
 
Figure 1. Results of the 15N HSQC titration of Gal-1 with lactose at pH 7.4. Top 15 
shifted residues are mapped (red) on the surface of the Gal-1 homodimer. 
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2. The Tyr-Xxx-Tyr peptide motif has been reported to be a glycomimetic sequence, 
mainly on the basis of its inhibitory effect on the Gal-1–ASF interaction. Our STD 
and trNOE NMR experiments revealed the following findings: 
2.1.  The Tyr-Xxx-Tyr peptides studied did not bind to Gal-1. 15N HSQC titrations 
with 15N-labelled Gal-1 confirmed the absence of any peptide–Gal-1 
interaction. 
2.2. The binding of Tyr-Xxx-Tyr peptides to ASF was clearly detected. 
2.3. The Tyr-Xxx-Tyr peptides proved effective in the competitive tests not 
because they were able to bind to Gal-1 and to replace ASF, but rather because 
of their interactions with the glycoprotein ASF (Figure 3). These data indicated 
that the Tyr-Xxx-Tyr peptides tested in this work are not glycomimetics as 
they interact with ASF via an unrevealed molecular linkage.  
 
Figure 3. Proposed mechanism for inhibition of the Gal-1–ASF interaction by Tyr-Xxx-Tyr 
type peptides. 
3. The NMR signal quenching of the neuroprotective pentapeptide LPFFD and the 
fluorescent dye ThT was studied in the presence of Aβ1-42 fibrils. The experiments 
yielded highly intriguing results:  
3.1.  ThT could not fully and immediately replace LPFFD from Aβ and could not 
prevent the weak binding of the pentapeptide, and LPFFD did not decrease the 
extent of the NMR spectroscopy-detected ThT binding, but rather increased it.  
3.2. No solution NMR spectroscopically visible monomeric or oligomeric Aβ1-42 
signal accompanied the resonances of the studied ligands in the spectra. 
3.3. The disaggregation mechanism of neuroprotective peptides is unlikely and 
ligand-induced flocculation and sedimentation processes could be proposed 
(Figure 4), which were confirmed by DLS and TEM experiments. 
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Figure 4. Schematic representation of the ligand-induced flocculation of fibrillar Aβ1-42 
by non-covalent cross-linking. 
4. A foldamer library was screened with STD and trNOE techniques testing their 
binding to soluble Aβ1-42 oligomers. 
4.1. A hexapeptide foldamer was found which exhibited weak binding to Aβ. The 
weak interaction could be enhanced by following the principles of multivalent 
ligands (Figure 5): the tetravalent generation-zero poly(amidoamine) conjugate 
of the peptide exhibited nanomolar binding to oligomers. The binding of the 
tetravalent compound showed a two-step-binding with a low nanomolar and a 
submicromolar apparent dissociation constants. 
4.2. Initial structure-activity relationship studies revealed that compounds with 
different recognition elements or with divalent construction exhibited only 
weak interaction, which suggests that the pharmacophore is specific. 
 
Figure 5. Applying the principle of multivalency to foldamers: a compound with 
nanomolar affinity for Aβ1-42 oligomers was achieved.  
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